Related Experiment Video

Updated: May 7, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.5K

Improvement of Laboratory Hepatic Parameters After Treatment With 177 Lu-DOTATATE : Cohort in an Oncology Reference

Filipe Dos Santos Soares1, Juliana Ribeiro de Carvalho2, Beatriz Arruda Matheos de Lima

  • 1From the Nuclear Medicine Service.

Clinical Nuclear Medicine
|August 1, 2024
PubMed
Abstract

Insights

Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE improved liver function and cholestasis markers in neuroendocrine neoplasm (NET) patients. Bone marrow function consistently decreased following treatment.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Biochemistry

Background:

  • Neuroendocrine neoplasms (NETs) overexpress somatostatin receptors, a target for peptide receptor radionuclide therapy (PRRT).
  • Liver metastasis in NETs is a critical prognostic factor, often leading to liver failure and death.
  • Assessing laboratory parameter changes post-PRRT is crucial for understanding treatment effects on liver function.

Purpose of the Study:

  • To evaluate the impact of 177 Lu-DOTATATE PRRT on laboratorial parameters, specifically focusing on hepatic function.
  • To analyze changes in liver function, cholestasis, kidney, and bone marrow function markers in NET patients undergoing PRRT.
  • To correlate changes in laboratory parameters with disease burden, particularly liver disease volume.

Main Methods:

  • Retrospective observational study of 110 patients treated with 1 to 4 cycles of 177 Lu-DOTATATE.
  • Blood tests were conducted before and after each PRRT cycle to monitor laboratory parameters.
  • Analysis included liver function tests, cholestasis markers, kidney function, and bone marrow function.

Main Results:

  • A statistically significant reduction in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) was observed in the overall patient population.
  • Patients with high liver disease volume showed a significant decrease in alanine aminotransferase (ALT).
  • All bone marrow function parameters significantly decreased across all patient subsets.

Conclusions:

  • 177 Lu-DOTATATE PRRT leads to significant improvements in liver function and cholestasis parameters in NET patients.
  • A consistent decrease in bone marrow function parameters was noted post-PRRT.
  • The therapeutic benefits on liver function were evident even in patients with advanced liver disease.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

399

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275